var data={"title":"Ferric citrate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ferric citrate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/752970?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ferric-citrate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ferric citrate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26536176\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Auryxia</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25816127\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Iron Salt;</li>\n      <li>\n        Phosphate Binder</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26176318\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Each tablet contains 210 mg of ferric iron equivalent to 1 g ferric citrate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperphosphatemia:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: Two tablets (420 mg ferric iron) 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance: Increase or decrease dose by 1 tablet or 2 tablets (ferric iron 210 mg to 420 mg) as needed at 1-week or longer intervals to achieve target serum phosphorus levels (maximum dose: 12 tablets [ferric iron 2,520 mg] daily).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Iron deficiency anemia (nondialysis CKD): </b>Oral: One tablet (ferric iron 210 mg) 3 times daily; titrate dose as needed to achieve and maintain target hemoglobin level (maximum dose: 12 tablets [ferric iron 2,520 mg] daily). <b>Note:</b> In one clinical trial, dose titration occurred at 4-week intervals to achieve desired hemoglobin levels; dose was increased only if serum phosphorus level &ge;3 mg/dL, was decreased if serum phosphorus level &lt;2.5 mg/dL, and temporarily discontinued if serum phosphorus level &lt;2 mg/dL (Fishbane 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26176319\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26176320\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26176321\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26111585\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Auryxia: Ferric iron 210 mg (ferric citrate 1 g) [contains fd&amp;c blue #2 aluminum lake, fd&amp;c red #40 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26111584\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26176339\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer with meals. Do not chew or crush tablets (may discolor mouth and teeth).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25816129\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperphosphatemia:</b> For the control of serum phosphorus levels in patients with chronic kidney disease (CKD) receiving dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Iron deficiency anemia: </b>Treatment of iron deficiency anemia in patients with CKD not on dialysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26431971\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Gastrointestinal: Darkening of stools (19% to 22%), diarrhea (21%), constipation (8% to 18%), nausea (10% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperkalemia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (7%), abdominal pain (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (6%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25816130\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Iron overload syndromes (eg, hemochromatosis)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26176304\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Iron toxicity: May increase serum iron, ferritin, and transferrin saturation (TSAT), which may lead to excessive elevations in iron stores. Evaluate serum iron, ferritin, and TSAT at baseline and during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Stool discoloration: May cause discolored (dark) stools related to iron content.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Iron supplements: Patients receiving parenteral iron supplementation may require a dose reduction or discontinuation when ferric citrate is initiated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Overdose: Contains iron, a leading cause of fatal poisoning in children &lt;6 years of age. Keep out of reach of children; in case of accidental overdose, immediately contact a poison control center or a health care provider.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25882716\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25882713\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=96959&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: Iron Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Iron Salts. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: Iron Salts may decrease the serum concentration of Bictegravir.  Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with iron salts under fed conditions, but coadministration with or 2 hours after an iron salt is not recommended under fasting conditions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Iron Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral iron supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<b> Exceptions: </b>Pamidronate; Zoledronic Acid.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefdinir: Iron Salts may decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex.  Management: Avoid concurrent cefdinir and oral iron when possible.  Separating doses by several hours may minimize interaction.  Iron-containing infant formulas do not appear to interact with cefdinir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Iron Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimercaprol: May enhance the nephrotoxic effect of Iron Salts.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: Iron Salts may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral iron. Administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral iron salts. Alternatively, dolutegravir and oral iron can be taken together with food.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: Iron Salts may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any iron-containing product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Entacapone: Iron Salts may decrease the serum concentration of Entacapone.  Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Iron Salts may decrease the serum concentration of Levodopa. Only applies to oral iron preparations.  Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levothyroxine: Iron Salts may decrease the serum concentration of Levothyroxine.  Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours.  Separation of doses is not required with parenterally administered iron salts or levothyroxine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methyldopa: Iron Salts may decrease the serum concentration of Methyldopa. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PenicillAMINE: Iron Salts may decrease the absorption of PenicillAMINE. Only oral iron salts are a concern. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphate Supplements: Iron Salts may decrease the absorption of Phosphate Supplements.  Management: Administer oral phosphate supplements as far apart from the administration of an oral iron salt as possible to minimize the significance of this interaction.<b> Exceptions: </b>Sodium Glycerophosphate Pentahydrate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Iron Salts may decrease the serum concentration of Quinolones.  Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for levo-, nor-, oflox-, pefloxacin, or nalidixic acid) oral iron salts<b> Exceptions: </b>LevoFLOXacin (Oral Inhalation).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May decrease the absorption of Iron Salts. Iron Salts may decrease the serum concentration of Tetracyclines.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trientine: May decrease the serum concentration of Iron Salts. Iron Salts may decrease the serum concentration of Trientine. Management: Trientine manufacturer recommends avoiding concurrent use with oral iron salts due to the risk for impaired GI absorption of both trientine and the iron salt. Short courses of iron may be used; however, separate administration by at least 2 hours.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26176301\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Use of ferric citrate may increase iron stores, which may cause adverse events in pregnancy (fetal malformations, spontaneous abortion, and gestational diabetes noted with iron overdose in pregnant women).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26176303\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if ferric citrate is present in breast milk; the manufacturer notes that exposure to a breastfeeding infant is possible. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26176338\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Ensure adherence with prescribed diet.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26176341\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum iron, ferritin, and transferrin saturation (TSAT) at baseline and during therapy; serum phosphorus (periodically)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26176308\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyperphosphatemia: Lowers serum phosphate by binding to dietary phosphate in the GI tract; product precipitates as insoluble ferric phosphate and is excreted in feces.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron deficiency anemia: Oxidized ferric iron circulates bound to transferrin where it is incorporated into hemoglobin after it is transported through enterocytes into the blood.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26116587\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Auryxia Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 GM210 MG(Fe) (200): $1,284.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50663160\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Riona (JP)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Auryxia (ferric citrate) [prescribing information]. Boston, MA: Keryx Biopharmaceuticals; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dwyer JP, Sika M, Schulman G, et al; Collaborative Study Group. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. <i>Am J Kidney Dis</i>. 2013;61(5):759-766.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferric-citrate-drug-information/abstract-text/23369827/pubmed\" target=\"_blank\" id=\"23369827\">23369827</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferric citrate [prescribing information]. New York, NY: Keryx Biopharmaceuticals; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28082519\"></a>Fishbane S, Block GA, Loram L, et al. Effects of ferric citrate in patients with nondialysis-dependent CKD and iron deficiency anemia. <i>J Am Soc Nephrol</i>. 2017;28(6):1851-1858. doi: 10.1681/ASN.2016101053<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferric-citrate-drug-information/abstract-text/28082519/pubmed\" target=\"_blank\" id=\"28082519\">28082519</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mutell R, Rubin JL, Bond TC, Mayne T. Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model. <i>Int J Nephrol Renovasc Dis</i>. 2013;6:79-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferric-citrate-drug-information/abstract-text/23662073/pubmed\" target=\"_blank\" id=\"23662073\">23662073</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thomas A, Peterson LE. Reduction of costs for anemia-management drugs associated with the use of ferric citrate. <i>Int J Nephrol Renovasc Dis</i>. 2014;7:191-201.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferric-citrate-drug-information/abstract-text/24899820/pubmed\" target=\"_blank\" id=\"24899820\">24899820</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 96959 Version 56.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F26536176\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F25816127\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F26176318\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F26176319\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F26176320\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F26176321\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F26111585\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F26111584\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F26176339\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F25816129\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F26431971\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F25816130\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F26176304\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F25882716\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F25882713\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F26176301\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F26176303\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F26176338\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F26176341\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F26176308\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F26116587\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F50663160\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/96959|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ferric-citrate-patient-drug-information\" class=\"drug drug_patient\">Ferric citrate: Patient drug information</a></li></ul></div></div>","javascript":null}